Apolipoprotein e levels in the cerebrospinal fluid of north Indian patients with Alzheimer's disease

American Journal of Alzheimer's Disease and other Dementias

Volumn 28, Issue 3, 2013, Pages 258-262

  Kandimalla, Ramesh J L ^a   Wani, Willayat Yousuf ^b   Anand, R ^b   Kaushal, Alka ^b   Prabhakar, Sudesh ^b   Grover, Vinod K ^b   Bharadwaj, Neerja ^b   Jain, Kajal ^b   Gill, Kiran Dip ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Alzheimer's disease; ApoE; cerebrospinal fluid; Indian population

Indexed keywords

APOLIPOPROTEIN E;

ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PROTEIN CEREBROSPINAL FLUID LEVEL;

EID: 84876705720     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317513481097     Document Type: Article

References (26)

1. Alzheimer's disease facts and figures. Alzheimers Dement. 2008 ; 4 (2). 110-133
2. Ashford JW, Mortimer JA. Non-familial Alzheimer's disease is mainly due to genetic factors. J Alzheimers Dis. 2002 ; 4 (3). 169-177
3. Panza F, Solfrizzi V, D'Introno A, et al. Genetics of late-onset Alzheimer's disease: vascular risk and beta-amyloid metabolism [article in Italian]. Recenti Prog Med. 2002 ; 93 (9). 489-497
4. Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging. 2004 ; 25 (5). 641-650
5. Lehtovirta M, Soininen H, Laakso MP, et al. SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele. J Neurol Neurosurg Psychiatry. 1996 ; 60 (6). 644-649
6. Small SA, Wu EX, Bartsch D, et al. Imaging physiologic dysfunction of individual hippocampal subregions in humans and genetically modified mice. Neuron. 2000 ; 28 (3). 653-664
7. Juottonen K, Lehtovirta M, Helisalmi S, Riekkinen PJ, Soininen H. Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon4 allele. J Neurol Neurosurg Psychiatry. 1998 ; 65 (3). 322-327
8. Dik MG, Deeg DJ, Bouter LM, Corder EH, Kok A, Jonker C. Stroke and apolipoprotein E epsilon4 are independent risk factors for cognitive decline: a population-based study. Stroke. 2000 ; 31 (10). 2431-2436
9. Kandimalla RJ, Prabhakar S, Binukumar BK, et al. Apo-Eepsilon4 allele in conjunction with Abeta42 and tau in CSF: biomarker for Alzheimer's disease. Curr Alzheimer Res. 2011 ; 8 (2). 187-196
10. Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sci. 2006 ; 31 (8). 445-454
11. Carter DB. The interaction of amyloid-beta with ApoE. Subcell Biochem. 2005 ; 38: 255-272
12. Lovestone S, Anderton B, Betts J, et al. Apolipoprotein E gene and Alzheimer's disease: is tau the link?. Biochem Soc Symp. 2001 ; 67: 111-120
13. Taddei K, Clarnette R, Gandy SE, Martins RN. Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. Neurosci Lett. 1997 ; 223 (1). 29-32
14. Blennow K, Hesse C, Fredman P. Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease. Neuroreport. 1994 ; 5 (18). 2534-2536
15. Gupta VB, Laws SM, Villemagne VL, et al. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology. 2011 ; 76 (12). 1091-1098
16. Lehtimaki T, Pirttila T, Mehta PD, Wisniewski HM, Frey H, Nikkari T. Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum Genet. 1995 ; 95 (1). 39-42
17. Slooter AJ, de Knijff P, Hofman A, et al. Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study. Neurosci Lett. 1998 ; 248 (1). 21-24
18. Panza F, Solfrizzi V, Colacicco AM, et al. Apolipoprotein E (APOE) polymorphism influences serum APOE levels in Alzheimer's disease patients and centenarians. Neuroreport. 2003 ; 14 (4). 605-608
19. Bertrand P, Poirier J, Oda T, Finch CE, Pasinetti GM. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res Mol Brain Res. 1995 ; 33 (1). 174-178
20. Linton MF, Gish R, Hubl ST, et al. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest. 1991 ; 88 (1). 270-281
21. Weisgraber KH. Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. J Lipid Res. 1990 ; 31 (8). 1503-1511
22. Ikewaki K, Zech LA, Brewer HB, Rader DJ. Comparative in vivo metabolism of apolipoproteins E2 and E4 in heterozygous apoE2/4 subjects. J Lab Clin Med. 2002 ; 140 (5). 369-374
23. Gregg RE, Zech LA, Schaefer EJ, Brewer HB. Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E. Science. 1981 ; 211 (4482). 584-586
24. Gregg RE, Zech LA, Schaefer EJ, Stark D, Wilson D, Brewer HB. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest. 1986 ; 78 (3). 815-821
25. Wahrle SE, Shah AR, Fagan AM, et al. Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Mol Neurodegener. 2007 ; 2: 7
26. Simon R, Girod M, Fonbonne C, et al. Total ApoE and ApoE4 Isoform Assays in an Alzheimer's Disease Case-control Study by Targeted Mass Spectrometry (n = 669): a Pilot assay for methionine-containing proteotypic peptides. Mol Cell Proteomics. 2012 ; 11 (11). 1389-1403